Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision

Biognosys’ DIA mass spectrometry unbiased proteomics platform.png 

 

Biognosys’ DIA proteomics analysis software, Spectronaut® 

 

 Biognosys’ DIA proteomics analysis software, Spectronaut® .png

 Alamar’s NULISA™ platform: a new standard in proteomic analysis

 

Alamar’s NULISA™ platform: a new standard in proteomic analysis

 

A Media Snippet accompanying this announcement is available by clicking on this link.

 

About Biognosys 

 

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. 

Sumber: